Nöromuskuler Kavşak Hastalıklarında Acil Yaklaşımlar
Özet
Nöromuskuler kavşak (NMK) organizasyonu, fizyolojisi ve özellikle Myastenia Gravis (MG), Lambert-Eaton Miyastenik Sendromu (LEMS) ve Botulismus gibi edinsel NMK hastalıklarına yönelik acil yaklaşımlar hayati öneme sahiptir. NMK fizyolojisinde aksiyon potansiyeli, asetilkolin (ACh) salınımı ve postsinaptik reseptörlerin aktivasyonu ile kas kasılmasını sağlar. En sık görülen edinsel NMK hastalığı olan MG, postsinaptik zardaki ACh reseptörlerine karşı gelişen otoantikorlar nedeniyle çizgili kaslarda güçsüzlük ve yorgunlukla karakterizedir. Solunum kaslarının felciyle solunum desteği gerektiren akut ve hayatı tehdit eden "Miyastenik Kriz" (MK), MG'nin en kritik acil durumudur. MK yönetiminde erken entübasyon, mekanik ventilasyon, non-invaziv ventilasyon (BiPAP) ile birlikte plazma değişimi (TPD) veya intravenöz immünglobülin (IVIg) ve yüksek doz kortikosteroid tedavileri esastır. Presinaptik VGCC antikorlarının neden olduğu LEMS proksimal güçsüzlükle seyrederken; Clostridium botulinum toksinlerinin SNARE kompleksini inaktive etmesiyle oluşan Botulismus ise kraniyal sinir felçleriyle başlayıp desenden flask paralizi ve solunum yetmezliğine yol açan tıbbi bir acildir. Botulismusta laboratuvar sonucu beklenmeden, ilk 24-48 saat içinde botulinum antitoksini uygulanması hayat kurtarıcıdır.
Neuromuscular junction (NMJ) organization, physiology, and emergency approaches to acquired NMJ disorders, specifically Myasthenia Gravis (MG), Lambert-Eaton Myasthenic Syndrome (LEMS), and Botulism, are of vital importance. In NMJ physiology, action potential triggers acetylcholine (ACh) release and post-synaptic receptor activation, enabling muscle contraction. MG, the most common acquired NMJ disorder, is characterized by fluctuating muscle weakness and fatigue caused by autoantibodies targeting post-synaptic ACh receptors. The most critical emergency in MG is "Myasthenic Crisis" (MC), an acute, life-threatening deterioration involving respiratory muscle weakness that necessitates ventilatory support. Essential management of MC includes early intubation, mechanical ventilation, non-invasive ventilation (BiPAP), combined with therapeutic plasma exchange (TPE) or intravenous immunoglobulin (IVIg), and high-dose corticosteroids. While LEMS, caused by presynaptic VGCC antibodies, presents with proximal weakness, Botulism is a neurotoxin-mediated medical emergency caused by Clostridium botulinum toxins inactivating the SNARE complex, which manifests as acute descending flaccid paralysis starting with cranial nerve palsies and leading to respiratory failure. In suspected botulism cases, timely administration of botulinum antitoxin within the first 24-48 hours without waiting for laboratory confirmation is a critical, life-saving intervention.
Referanslar
Rizzoli SO, Betz WJ. Synaptic vesicle pools. Nat Rev Neurosci 2005;6: 57-69. doi:10.1038/nrn1583
Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol. 2001;64:393-429. doi: 10.1016/S0301-0082(00)00055-1
Zucker RS, Kullmann DM, Kaeser PS. Release of Neurotransmitters(Chapter 15). Byrne JH, Heidelberger R, Waxham MN (ed.) From Molecules to Networks II(third edition). Elsevier Inc; 2014 443-488. doi: 10.1016/B978-0-12-397179-1.00015-4
Rizo, J, Xu, J. The synaptic vesicle release machinery. Annu. Rev. Biophys. 2015; 44: 339–367. doi: 10.1146/annurev-biophys-060414-034057
Lee S, Shin J, Jung Y, et al. Munc18-1 induces conformational changes of syntaxin-1 in multiple intermediates for SNARE assembly. Sci Rep. 2020;10: 11623.doi: 10.1038/s41598-020-68476-3
Trinidad JC. Synaptosomes and Synaptic Vesicles. Bradshaw R, Stahl P (ed). Encyclopedia of Cell Biology II. Elsevier Inc. 2016. 293–301. doi:10.1016/B978-0-12-394447-4.20025-4
Ramakrishnan S, Bera M, Coleman J. Synergistic roles of Synaptotagmin-1 and complexin in calcium- regulated neuronal exocytosis. Elife. 2020; 9: 2-18. doi: 10.7554/eLife.54506
Ohkawara B, Ito M, Ohno K. Secreted Signaling Molecules at the Neuromuscular Junction in Physiology and Pathology. Int J Mol Sci. 2021; 22(5): 2455. doi: 10.3390/ijms22052455
Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle & Nerve. 2000; 23(4), 453–477. doi:10.1002/(sici)1097-4598(200004)23:4<453::aid-mus3>3.0.co;2-o
Mazman S, Odabaşı Z. Nöromusküler kavşak fizyolojisi. Tanrıdağ T(ed.), Nöromusküler Kavşak hastalıkları, Türkiye klinikleri, 2019; özel sayı: 6-15
Nishimune H, Shigemoto K. Practical Anatomy of the Neuromuscular Junction in Health and Disease. Neurologic Clinics. 2018; 36(2), 231–240. doi:10.1016/j.ncl.2018.01.009
Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010; 10: 46-54. doi: 10.1186/1471-2377-10-46
Gilhus NE. Autoimmune myasthenia gravis. Expert Review of Neurotherapeutics. 2009; 9(3): 351–8. doi: 10.1586/14737175.9.3.351
Bubuioc AM, Kudebayeva A, Turuspekova S. The epidemiology of myasthenia gravis. Journal of medicine and life. 2021; 14: 7-16. doi: 10.25122/jml-2020-0145
Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology.2021, 96 (3) 114-122; doi: 10.1212/WNL.0000000000011124
Avidan N, Panse RL, Berrih-Aknin S. Genetic basis of myasthenia gravis– A comprehensive review. Journal of Autoimmunity. 2014; 52: 146-153. doi: 10.1016/j.jaut.2013.12.001
Lopomo A, Berrih-Aknin S. Autoimmune thyroiditis and myasthenia gravis. Front Endocrinol. 2017; 8: 1–8. doi: 10.3389/fendo.2017.00169
Nancy P, Berrih-Aknin S. Differential estrogen receptor expression in autoimmune myasthenia gravis. Endocrinology. 2005;146(5):2345–53. doi: 10.1210/en.2004-1003
Silva JAPD. Sex hormones and glucocorticoids: Interactions with the immune system. Annals of the New York Academy of Sciences. 1999; 876: 102–18.doi:10.1111/j.1749-6632.1999.tb07628.x
Restivo DA, Centonze D, Alesina A, et al. Myasthenia Gravis Associated With SARS-CoV-2 Infection. Ann Intern Med. 2020; 2: 2019–20. doi:10.7326/L20-0845
Nemet AY, Kaiserman I, Mimouni M, et al. High prevalence of myasthenia gravis among rural adult populations. J Clin Neuromuscul Dis. 2014;16(2):47–50. doi:10.1097/CND. 0000000000000054
Samih M, Ahami AOT. Excessive pesticide use likely to cause the onset of Myasthenia gravis in the Moroccan agricultural population. Pakistan J Biol Sci. 2020;23(7):917–21. doi: 10.3923/pjbs.2020.917.921
Dresser L, Wlodarski R, Rezania K, et al. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. Jour Clin Med. 2021; 10(11): 2235. doi: 10.3390/jcm10112235
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–36. doi:10.1016/S1474-4422(15)00145-3
Szczudlik P, Szyluk B, Lipowska M, et al. Antititin Antibody in Early- and Late-Onset Myasthenia Gravis. Acta Neurol. Scand. 2014;130:229–233. doi: 10.1111/ane.12271
Kufukihara K, Watanabe Y, Inagaki T, et al. Cytometric Cell-Based Assays for Anti-Striational Antibodies in Myasthenia Gravis with Myositis and/or Myocarditis. Sci. Rep. 2019;9:5284. doi: 10.1038/s41598-019-41730-z
Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40. doi: 10.1002/mus.22006
Rodolico C, Toscano A, Autunno M. Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases. Neuromuscular Disorders. 2002; 12: 964–969. doi:10.1016/s0960-8966(02)00137-2
Nair AG, Patil-Chhablani P, Venkatramani DV, et al. Ocular myasthenia gravis: A review. Indian J Ophthalmol. 2014; 62(10): 985–991. doi: 10.4103/0301-4738.145987
Bekircan-Kurt CE, Kurne A, Erdem Ozdamar S, et al. Myasthenia gravis; single entity, variable clinical features: Ten years of clinical experience in a tertiary care center ten years clinical experience of a tertiary care center. J Neurol Sci-Turk. 2013;30:135-43.
Godoy DA, Mello LJ, Masotti L, et al. The myasthenic patient in crisis: an update of the management in Neurointensive care unit. Arq Neuropsiquiatr. 2013;71(9A):627–639. doi: 10.1590/0004-282X2013010
Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1:16-22. doi: 10.1177/1941875210382918
König N, Stetefeld HR, Dohmen C, et al. MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation. J Neurol. 2021; 268(12):4824–4833. 2021 May 10. doi: 10.1007/s00415-021-10603-9
Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology. 2020;94(3):299–313. doi:10.1212/WNL.0000000000008688
Stetefeld H, Schroeter M. SOP myasthenic crisis. Neurological Research and Practice. 2019;1(1):19-24. doi:10.1186/s42466-019-0023-3
Lacomis D. Myasthenic crisis. Neurocrit Care. 2005;3:189–194. doi:10.1385/NCC:3:3:189
Elsheikh B, Arnold WD, Gharibshahi S, et al. Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis. Muscle Nerve. 2016;53: 134-6. doi:10.1002/mus.24929
Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in us hospitals. Neurology. 2009; 72: 1548-54. doi:10.1212/WNL.0b013e3181a41211
Baraka A. Anaesthesia and myasthenia gravis. Can J Anaesth. 1992;39:476–486.
Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48:1253–1260. doi:10.1212/WNL.48.5.1253
Rabinstein AA, Mueller-Kronast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care. 2005;3:213–215. doi:10.1385/NCC:3:3:213
Wu JY, Kuo PH, Fan PC, et al. The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis. Neurocrit Care. 2009;10:35–42. doi: 10.1007/s12028-008-9139-y
O’Riordan JI, Miller DH, Mottershead JP, et al. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol. 1998;5:137–142. doi:10.1046/j.1468-1331.1998.520137.x
Seneviratne J, Mandrekar J, Wijdicks EF, et al. Predictors of extubation failure in myasthenic crisis. Arch Neurol. 2008;65:929–933. doi:10.1001/archneur.65.7.929
Varelas PN, Chua HC, Natterman J, et al. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med. 2002;30:2663–2668.
Seneviratne J, Mandrekar J, Wijdicks EF, et al. Noninvasive Ventilation in Myasthenic Crisis. Arch Neurol . 2008; 65 :54–58. doi:10.1001/archneurol.2007.1
Ciafaloni E. Myasthenia gravis and congenital myasthenic syndromes. Continuum. 2019; 25(6): 1767-1784. doi: 10.1212/CON.0000000000000800.
Sonkar KK, Bhoi SK, Dubey D, et al. Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India. J Clin Neurosci. 2017;38:114–117. doi: 10.1016/j.jocn.2016.11.003.
Prado MB, Adiao KJ. Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies. Neurocrit Care. 2021;22 :1–17. doi: 10.1007/s12028-021-01259-4
Sonkar KK, Bhoi SK, Dubey D, et al. Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India. J Clin Neurosci. 2017;38:114–117. doi: 10.1016/j.jocn.2016.11.003.
Mishra SK, Krishnappa S, Bhat RR. Role of intermittent noninvasive ventilation in anticholinesterase dose adjustment for myasthenic crisis. Acta Anaesthesiol Taiwanica. 2010;48(1):53–54. doi: 10.1016/S1875-4597(10)60012-4
Comerci G, Buffon A, Biondi-Zoccai GGL, et al. Coronary vasospasm secondary to hypercholinergic crisis: An iatrogenic cause of acute myocardial infarction in myasthenia gravis. Int J Cardiol. 2005; 103 (3):335–337. doi:10.1016/j.ijcard.2004.06.026
Shivamurthy P, Parker MW. Cardiac manifestations of myasthenia gravis: A systematic review. IJC Metab Endokr. 2014; 5 :3–6. doi:10.1016/j.ijcme.2014.08.003
Ahmed S, Kirmani JF, Janjua N, et al. An update on myasthenic crisis. Curr Treat Options Neurol. 2005 Mar;7(2):129–141. doi: 10.1007/s11940-005-0022-2
Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007;261(1–2):127–133. doi: 10.1016/j.jns.2007.04.045
Ipe TS, Davis AR, Raval JS. Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence. Front Neurol. 2021;12. doi:10.3389/fneur.2021.662856
Dogra A, Rana K, Rathod C, et al. Outcome of therapeutic plasma exchange in Myasthenia gravis patients. J Family Med Prim Care. 2020; 9(12):5971-5975. doi: 10.4103/jfmpc.jfmpc_1026_20
Titulaer MJ, Lang B and Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-107. doi: 10.1016/S1474-4422(11)70245-9
Nicolle MW. Myasthenia gravis and Lambert Eaton myasthenic syndrome. Continuum 2016;22(6):1978-2005. doi: 10.1212/CON.0000000000000415
Wirtz PW, Nijnuis MG, Sotodeh M, et al. Dutch Myasthenia Study Group. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J. Neurol. 2003;250:698–701. doi: 10.1007/s00415-003-1063-7
Baslo MB, Deymeer F, Serdaroglu P, et al. Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis. Neuromuscul. Disord. 2006;16:454–458. doi: 10.1016/j.nmd.2006.05.009
Sanders DB, Cao L, Massey JM, et al. Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis? Clin. Neurophysiol. 2014;125:1274–1277. doi: 10.1016/j.clinph.2013.11.007
Rao AK, Sobel J, Stephens KC, et al. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 2021; 70(2): 1–30. doi: 10.15585/mmwr.rr7002a1
Humeau Y, Doussau F, Grant NJ, et al. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000;82:427–46. doi:10.1016/S0300-9084(00)00216
Rosow LK, Strober JB. Infant botulism: review and clinical update. Pediatr Neurol. 2015; 52(5):487-92. doi: 10.1016/j.pediatrneurol.2015.01.006
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014; 12(8):535-49. doi: 10.1038/nrmicro3295
Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975–1988. J Infect Dis 1992;166:1281–6. doi: 10.1093/infdis/166.6.1281
Chatham-Stephens K, Fleck-Derderian S, Johnson SD, et al. Clinical features of foodborne and wound botulism: a systematic review of the literature, 1932–2015. Clin Infect Dis 2017;66(suppl_1):11–6. doi:10.1093/cid/cix811
Rao AK, Lin NH, Griese SE, et al. Clinical criteria to trigger suspicion for botulism: an evidence-based tool to facilitate timely recognition of suspected cases during sporadic events and outbreaks. Clin Infect Dis 2017;66(suppl_1):38–42. doi:10.1093/cid/cix814
Potulska-Chromik A, Zakrzewska-Pniewska B, Szmidt-Sałkowska E, et al. Long lasting dysautonomia due to botulinum toxin B poisoning: clinical-laboratory follow up and difficulties in initial diagnosis. BMC Res Notes 2013;6:438. doi: 10.1186/1756-0500-6-438
Schussler E, Sobel J, Hsu J, et al. Workgroup report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup—Allergic reactions to botulinum antitoxin: a systematic review. Clin Infect Dis 2017;66(suppl_1):S65–72. doi: 10.1093/cid/cix827
